Novanta AI Stock Analysis
Want to see NOVT full AI Analyst Report?
Novanta (NOVT) AI Stock Analysis
Novanta
(NASDAQ:NOVT)
NOVT scores as moderately attractive overall: the biggest positives are improving cash generation and strong, upbeat guidance with expected EBITDA/cash-flow growth. Offsetting these are compressed profitability and higher debt, plus weak technical trends and a very high P/E valuation that increases execution risk.
Novanta Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across regions, revealing where Novanta earns its sales and how exposed the company is to local demand cycles, regulatory differences, or currency swings. Helps gauge growth opportunities in different markets and identify concentration risk if a large share comes from one region.
Novanta's top-line is being driven by the U.S., which accounts for the bulk of revenue and has shown consistent acceleration; non-U.S. markets—notably China and Rest of Europe—have rebounded recently, helping offset weakness in Germany and small 'Other' markets. Management's booking growth and surging design wins validate the geographic recovery and support mid-single-digit organic guidance, but call details flag an underlying organic revenue contraction and Precision Medicine softness that could blunt near-term upside if bookings don't convert.
Novanta (NOVT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.33B
- Dividend Yield
- ―
- Average Volume (3M)
- 434.63K
- Price to Earnings (P/E)
- 86.3
- Beta (1Y)
- 1.73
- Revenue Growth
- 13.18%
- EPS Growth
- -9.22%
- Country
- US
- Employees
- 3,000
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Hardware, Equipment & Parts
Novanta Business Overview & Revenue Model
Company Description
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplie...
How the Company Makes Money
Novanta makes money primarily by selling engineered components, modules, and subsystems to OEM customers, generating revenue largely from product sales recognized when control transfers under customer contracts. Key revenue streams generally align to...
Novanta Earnings Call Summary
The call was strongly positive overall. Novanta reported broad-based revenue, organic growth, bookings, backlog, adjusted EBITDA, adjusted EPS, and cash-flow gains; completed and integrated its largest acquisition; and highlighted substantial product, design-win, and end-market momentum. The principal challenges were temporary Stockport production and shipment issues, lower near-term gross margins, a decline in precision medicine revenue, manufacturing-transition costs, tight component supply, and higher leverage after the acquisition. Management characterized the major operational issues as temporary and maintained strong 2026 and 2027 growth expectations.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter of 2026, Novanta expects GAAP revenue to be approximately $306 million-$312 million, reported growth of 18% to 21%, organic revenue growth of 5% to 7%, and approximately $35 million of revenue from Riverpoint Medical; adjusted EBITDA is expected to be between $76 million and $79 million, representing growth of 25%-30% year over year and approximately 25% EBITDA margin, approximately 150 basis points higher than the prior year, while adjusted diluted earnings per share is expected to be in the range of $0.91-$0.96. For full-year 2026, it expects GAAP revenue of approximately $1,135 million -$1,140 million, reported growth of approximately 16%, organic growth of approximately 7%, adjusted gross margins of approximately 46.5%, non-GAAP operating expenses of approximately 27% of sales, depreciation expense of approximately $19 million, stock compensation expense of approximately $38 million, interest expense of approximately $23 million, a non-GAAP tax rate of approximately 21%, diluted weighted average shares outstanding of approximately 42 million, adjusted EBITDA between $274 million and $277 million, year-over-year growth of 24%-25%, adjusted diluted earnings per share in the range of $3.66 to $3.71, year-over-year growth of 11%-13%, operating cash flow of approximately $200 million, year-end gross debt of approximately $818 million, gross leverage ratio of 2.6x, and net leverage of approximately 2.1. Medical Solutions is expected to deliver 2% to 4% organic growth, Automation Enabling Technologies had an outlook of 12% to14% growth, precision medicine is expected to return to growth in late 2027, production in Stockport is expected to resume in the first quarter, and Novanta currently expects a 2027 outlook of more than 15% reported growth and more than 20% adjusted EBITDA growth, with gross margins expected to expand at least 100 basis points next year and a long-term algorithm of mid to high single-digit organic growth.
Novanta Financial Statement Overview
Summary
Financials are solid but not standout: steady TTM revenue growth (~$1.09B) and strong free cash flow (~$140M) support the profile, but profitability has compressed (TTM net margin ~4.9% vs higher levels in 2022–2024) and total debt stepped up meaningfully in the latest TTM period, increasing balance-sheet risk if margins don’t recover.
Income Statement
64PositiveBalance Sheet
67PositiveCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.09B | 980.60M | 949.25M | 881.66M | 860.90M | 706.79M |
| Gross Profit | 469.50M | 407.81M | 421.55M | 399.90M | 378.47M | 300.33M |
| EBITDA | 158.84M | 153.05M | 179.86M | 169.92M | 160.62M | 125.47M |
| Net Income | 53.13M | 53.83M | 64.09M | 72.88M | 74.05M | 50.33M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 1.81B | 1.39B | 1.23B | 1.24B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 149.22M | 380.87M | 113.99M | 105.05M | 100.11M | 117.39M |
| Total Debt | 893.25M | 341.61M | 471.00M | 404.56M | 489.38M | 493.40M |
| Total Liabilities | 1.55B | 492.82M | 642.81M | 552.60M | 663.63M | 706.59M |
| Stockholders Equity | 1.62B | 1.31B | 745.70M | 673.46M | 577.59M | 521.29M |
Cash Flow | ||||||
| Free Cash Flow | 140.44M | 48.43M | 141.35M | 100.11M | 71.14M | 72.45M |
| Operating Cash Flow | 164.69M | 64.06M | 158.51M | 120.08M | 90.78M | 94.63M |
| Investing Cash Flow | -1.22B | -74.32M | -208.19M | -19.89M | -42.54M | -306.70M |
| Financing Cash Flow | 1.12B | 276.33M | 56.94M | -97.85M | -60.15M | 204.75M |
Novanta Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Negative. The current price of 114.40 is below the 20-day moving average (MA) of 137.18, below the 50-day MA of 139.61, and below the 200-day MA of 142.02, indicating a bearish trend. The MACD of -6.01 indicates Positive momentum. The RSI at 33.73 is Neutral, neither overbought nor oversold. The STOCH value of 8.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NOVT.
Novanta Risk Analysis
Novanta disclosed 38 risk factors in its most recent earnings report. Novanta reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksNovanta Peers Comparison
Overall Rating
MKSI77Outperform
TDY77Outperform
CGNX73Outperform
OSIS68Neutral
COHR63Neutral
NOVT62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $13.82B | 22.94 | 20.40% | 0.48% | 24.53% | 116.17% | |
| 77Outperform | $28.91B | 28.60 | 9.49% | ― | 8.43% | 26.65% | |
| 73Outperform | $8.12B | 33.38 | 15.31% | 0.71% | 15.82% | 121.72% | |
| 68Neutral | $2.96B | 19.65 | 18.92% | ― | 2.91% | 6.65% | |
| 63Neutral | $40.07B | 40.03 | 9.30% | ― | 30.84% | 582.28% | |
| 62Neutral | $4.33B | 86.29 | 3.62% | ― | 13.18% | -9.22% | |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NOVT | Novanta | 114.40 | 13.75 | 13.66% | |
| CGNX | Cognex | 48.20 | 12.25 | 34.09% | |
| COHR | Coherent Corp. | 203.43 | 60.49 | 42.32% | |
| MKSI | Mks Inc. | 204.38 | 61.12 | 42.66% | |
| OSIS | OSI Systems | 188.31 | -49.51 | -20.82% | |
| TDY | Teledyne | 627.95 | 134.01 | 27.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
